Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Nivolumab and sunitinib combination in advanced soft tissue sarcomas: a multicenter, single-arm, phase Ib/II trial
Javier Martín‐Broto, Nadia Hindi, Giovanni Grignani, et al.
Journal for ImmunoTherapy of Cancer (2020) Vol. 8, Iss. 2, pp. e001561-e001561
Open Access | Times Cited: 126

Showing 1-25 of 126 citing articles:

Combination therapy with immune checkpoint inhibitors (ICIs); a new frontier
Somayeh Vafaei, Angelina Olegovna Zekiy, Ramadhan Ado Khanamir, et al.
Cancer Cell International (2022) Vol. 22, Iss. 1
Open Access | Times Cited: 167
A Comprehensive Review on Solitary Fibrous Tumor: New Insights for New Horizons
Javier Martín‐Broto, José L. Mondaza-Hernández, David S. Moura, et al.
Cancers (2021) Vol. 13, Iss. 12, pp. 2913-2913
Open Access | Times Cited: 105
Atezolizumab for Advanced Alveolar Soft Part Sarcoma
Alice Chen, Elad Sharon, Geraldine O’Sullivan Coyne, et al.
New England Journal of Medicine (2023) Vol. 389, Iss. 10, pp. 911-921
Open Access | Times Cited: 66
New clinical trial design in precision medicine: discovery, development and direction
Xiao-Peng Duan, Bao‐Dong Qin, Xiao‐Dong Jiao, et al.
Signal Transduction and Targeted Therapy (2024) Vol. 9, Iss. 1
Open Access | Times Cited: 49
Pembrolizumab in patients with rare and ultra-rare sarcomas (AcSé Pembrolizumab): analysis of a subgroup from a non-randomised, open-label, phase 2, basket trial
Jean‐Yves Blay, Sylvie Chevret, Axel Le Cesne, et al.
The Lancet Oncology (2023) Vol. 24, Iss. 8, pp. 892-902
Closed Access | Times Cited: 43
Advances on immunotherapy for osteosarcoma
Shengnan Yu, Xudong Yao
Molecular Cancer (2024) Vol. 23, Iss. 1
Open Access | Times Cited: 37
UK guidelines for the management of soft tissue sarcomas
Andrew Hayes, Ioanna Nixon, D. Strauß, et al.
British Journal of Cancer (2024)
Open Access | Times Cited: 18
Cancer-associated fibroblasts as therapeutic targets for cancer: advances, challenges, and future prospects
Zhipeng Cao, Sadia Quazi, Sakshi Arora, et al.
Journal of Biomedical Science (2025) Vol. 32, Iss. 1
Open Access | Times Cited: 6
Immune checkpoint inhibitors in treatment of soft-tissue sarcoma: A systematic review and meta-analysis
Michael Saerens, Nele Brusselaers, Sylvie Rottey, et al.
European Journal of Cancer (2021) Vol. 152, pp. 165-182
Open Access | Times Cited: 86
Improving Immunotherapy Efficacy in Soft-Tissue Sarcomas: A Biomarker Driven and Histotype Tailored Review
Matthieu Roulleaux Dugage, Elise F. Nassif, Antoîne Italiano, et al.
Frontiers in Immunology (2021) Vol. 12
Open Access | Times Cited: 60
Immunosuppressive Effects of Myeloid-Derived Suppressor Cells in Cancer and Immunotherapy
Mithunah Krishnamoorthy, Lara Gerhardt, Saman Maleki Vareki
Cells (2021) Vol. 10, Iss. 5, pp. 1170-1170
Open Access | Times Cited: 59
Advances in CAR-T Cell Genetic Engineering Strategies to Overcome Hurdles in Solid Tumors Treatment
Alain E. Andrea, Andrada Chiron, Sarah Mallah, et al.
Frontiers in Immunology (2022) Vol. 13
Open Access | Times Cited: 44
Immunotherapy for SMARCB1-Deficient Sarcomas: Current Evidence and Future Developments
Carine Ngo, Sophie Postel‐Vinay
Biomedicines (2022) Vol. 10, Iss. 3, pp. 650-650
Open Access | Times Cited: 40
The application and research progress of anti-angiogenesis therapy in tumor immunotherapy
Jingyao Tu, Hang Liang, Chunya Li, et al.
Frontiers in Immunology (2023) Vol. 14
Open Access | Times Cited: 29
Durvalumab plus pazopanib combination in patients with advanced soft tissue sarcomas: a phase II trial
Hee Jin Cho, Kum‐Hee Yun, Su‐Jin Shin, et al.
Nature Communications (2024) Vol. 15, Iss. 1
Open Access | Times Cited: 14
Immunotherapy in Sarcoma: Current Data and Promising Strategies
Georgina Wood, Christian F. Meyer, Florent Petitprez, et al.
American Society of Clinical Oncology Educational Book (2024) Vol. 44, Iss. 3
Closed Access | Times Cited: 11
Immunotherapy in soft tissue and bone sarcoma: unraveling the barriers to effectiveness
Myrofora Panagi, Pampina Pilavaki, Anastasia Constantinidou, et al.
Theranostics (2022) Vol. 12, Iss. 14, pp. 6106-6129
Open Access | Times Cited: 31
High Levels of Circulating Monocytic Myeloid-Derived Suppressive-Like Cells Are Associated With the Primary Resistance to Immune Checkpoint Inhibitors in Advanced Non-Small Cell Lung Cancer: An Exploratory Analysis
Giuseppe Bronte, Elisabetta Petracci, Serena De Matteis, et al.
Frontiers in Immunology (2022) Vol. 13
Open Access | Times Cited: 29
Promise and Challenges of T Cell Immunotherapy for Osteosarcoma
Jeong A Park, Nai‐Kong V. Cheung
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 15, pp. 12520-12520
Open Access | Times Cited: 18
Phase II study of pembrolizumab and lenvatinib in advanced well-differentiated neuroendocrine tumors
Taymeyah Al‐Toubah, Michael J. Schell, Brian Morse, et al.
ESMO Open (2024) Vol. 9, Iss. 4, pp. 102386-102386
Open Access | Times Cited: 6
Systematic Review of Recurrent Osteosarcoma Systemic Therapy
Ioanna Gazouli, Anastasios Kyriazoglou, Ioannis Kotsantis, et al.
Cancers (2021) Vol. 13, Iss. 8, pp. 1757-1757
Open Access | Times Cited: 40
Phase II Study of TQB2450, a Novel PD-L1 Antibody, in Combination with Anlotinib in Patients with Locally Advanced or Metastatic Soft Tissue Sarcoma
Jiayong Liu, Tian Gao, Zhichao Tan, et al.
Clinical Cancer Research (2022), pp. OF1-OF7
Open Access | Times Cited: 27
Systemic treatment of advanced clear cell sarcoma: results from a retrospective international series from the World Sarcoma Network
Alannah Smrke, Anna Maria Frezza, Claudia Giani, et al.
ESMO Open (2022) Vol. 7, Iss. 3, pp. 100522-100522
Open Access | Times Cited: 23
Clear cell sarcoma: state-of-the art and perspectives
Laureline Wetterwald, Nicolò Riggi, Anastasios Kyriazoglou, et al.
Expert Review of Anticancer Therapy (2023) Vol. 23, Iss. 3, pp. 235-242
Closed Access | Times Cited: 15
Targeted and immuno-based therapies in sarcoma: mechanisms and advances in clinical trials
Fan Tang, Yan Tie, Yuquan Wei, et al.
Biochimica et Biophysica Acta (BBA) - Reviews on Cancer (2021) Vol. 1876, Iss. 2, pp. 188606-188606
Open Access | Times Cited: 31
Page 1 - Next Page

Scroll to top